Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19 by Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko

Get full text

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study. by Ekaterina A Bryushkova, Valeria D Skatova, Zinaida Y Mutovina, Alena I Zagrebneva, Daria S Fomina, Tatyana S Kruglova, Anna A Akopyan, Irina D Strazhesko, Sergey A Lukyanov, Olga N Tkacheva, Maryana A Lysenko, Dmitry M Chudakov

Get full text

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period by Daria S. Fomina, Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg, Alexander L. Gintsburg

Get full text